NCT02437110View on ClinicalTrials.gov

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

PHASE1CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 17, 2022

Study Completion Date

May 9, 2023

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Darunavir

Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.

DRUG

Ritonavir

Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.

DRUG

Dolutegravir

Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.

DRUG

Tenofovir alafenamide (TAF)

Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT02437110 - HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter